The Goldilocks Criteria – Rationale for antibody fragments in radiopharmaceutical therapy.

Time: 12:00 pm
day: Day One


  • Radiopharmaceutical Therapy (RPT) is gaining significant research interest in recent years. Many of the agents focused on delivering RPT to date have focused on small molecules (including peptides) or intact antibodies. This talk will focus on the utility of antibody fragment technologies to deliver RPT
  • Antibody fragments such as nanobodies, diabodies, and minibodies offer the potential to deliver optimal pharmacokinetics for RPT payload delivery through intermediate and tuneable blood clearance, tumor penetration and tumor uptake when compared with equivalent small molecules or antibodies to a tumor target
  • Recent development in the field of antibody fragments will be discussed with a particular focus on “ The Goldilocks Criteria” and how this broad class of compounds could be just right for the future of RPT in cancer